Selective Androgen Receptor Degrader (SARD) technology is being evaluated as a potentially novel treatment for men with castration-resistant prostate cancer (CRPC), including those who do not respond, or are resistant, to currently approved therapies. The Company believes that its SARD compounds will degrade multiple forms of the androgen receptor (AR), including AR variants, such as AR-V7.
The Company has optimized and selected lead preclinical compounds and has initiated a later-stage preclinical development program so that it can select the best SARD compounds for continued development. The Company plans to initiate its first clinical trial with a SARD in CRPC in 2017.
More information on Prostate Cancer may be found here.